oncosecOncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, has named Adil Daud, M.D. as Chief Clinical Strategist.

Dr. Daud is a longstanding member of OncoSec’s Melanoma Advisory Board and serves as Principal Investigator for OncoSec’s Phase 2 melanoma study. He is a clinical professor of hematology/oncology at University of California, San Francisco (UCSF), and Director of … Read more

nxtcpNXT-ID, Inc., (NXTD) a biometric authentication company focused on the growing m-commerce market announces the roll out of the first 30 second ads to be aired on CNBC starting the week of May 12th. The consumer ads will feature the company’s next generation smart wallet, Wocket™, created to securely replace all the credit cards and loyalty cards in your wallet.… Read more

19SurePure, Inc. (SURP) a global leader in liquid photopurification, today announced a breakthrough in the microbiological purification of contaminated marine diesel fuel, using SurePure’s technology as an alternative to biocide addition or excessive micro-filtration.

The contamination of diesel fuel is a significant problem for the maritime shipping industry, leading to extensive waste of fuel and environmental contamination. The industry is seeking … Read more

championChampions Oncology, Inc. (CSBR)

WST: Can you begin with a brief overview of Champions Oncology’s business?

Mr. Ackerman: We are in the business of personalizing both the treatment as well as the development of drugs for oncology. One of the major problems in oncology today is most patients get little or no benefit from most of the drugs they take. The fundamental reason is the … Read more

oncosecOncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, has appointed Jean S. Campbell, Ph.D. as Executive Director of Research and Development, a newly created position. Dr. Campbell, an Associate Professor in the Department of Pathology in the School of Medicine at the University of Washington, Seattle, will leverage her considerable expertise in cancer biology and signal … Read more

myphoto1Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will participate in RedChip’s Global Online CEO Conference on Thursday, April 24, 2014.

Dr. Kaushik J. Dave, President and CEO of Actinium, will be reviewing the Company’s clinical development and strategy in his presentation that will be held at 12:30 … Read more

ScreenshotAthersys, Inc. (ATHX) will release its first quarter 2014 financial results at approximately 4:00 PM (Eastern Time) on Thursday, May 8, 2014, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:

Read more


12zsTargeted Medical Pharma (TRGM), today announced the completion of an agreement between Analytical Testing Laboratories (ATL), a Lebanon based company that specializes in drug testing services and inborn errors of metabolism, for the exclusive distribution of the company’s amino acid based products to physicians and pharmacies throughout the Middle East.

The Agreement provides ATL with a limited exclusive license for the marketing and … Read more

clrxCollabRx, Inc. (CLRX), a leading provider of software and IT systems that support clinical decision-making in oncology, and Affymetrix, Inc. (AFFX), an industry leader in genomics analysis, today announced an agreement to optimize the use of CollabRx’s Genetic Variant Annotation (GVA) Service(TM) in connection with Affymetrix’ OncoScan(TM) FFPE Assay Kit and CytoScan(R) Cytogenetics Suite … Read more

ScreenHunter_186-Mar.-12-11.04Champions Oncology Treating cancer has long been a trial and error process for doctors, but Champions Oncology is hoping to take the guess work out of choosing the right therapy through the use of its mouse avatars. The company engrafts a patient’s tumor in mice to determine what drugs are most effective. We spoke to Joel Ackerman, CEO of Champions Oncology, about the personalization of … Read more